Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma

BACKGROUND: Malignant melanoma is an immunogenic skin cancer with an increasing global incidence. Advanced stages of melanoma have poor prognoses. Currently, there are no reliable parameters to predict a patient's response to immune checkpoint inhibitor (ICI) therapy. METHODS: This study highli...

Descripción completa

Detalles Bibliográficos
Autores principales: Krebs, Franziska K., Trzeciak, Emily R., Zimmer, Sophia, Özistanbullu, Deniz, Mitzel‐Rink, Heidrun, Meissner, Markus, Grabbe, Stephan, Loquai, Carmen, Tuettenberg, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940230/
https://www.ncbi.nlm.nih.gov/pubmed/33449393
http://dx.doi.org/10.1002/cam4.3710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940230/
https://www.ncbi.nlm.nih.gov/pubmed/33449393
http://dx.doi.org/10.1002/cam4.3710

Ejemplares similares